Targeted Immunotherapy Trials for Idiopathic Inflammatory Myopathies

Overview

Journal J Neurol

Specialty Neurology

Date 2012 Jul 4

PMID 22752063

Authors

Joerg-Patrick Stubgen

Affiliations

Soon will be listed here.

Abstract

The idiopathic inflammatory myopathies (IIM) are a group of muscle diseases with complex immunopathogenesis that varies between disease subgroups, and possibly between patients within the same subgroup. There exists no universal consensus on optimum management, so that no "standard" therapy has been developed. Treatment-refractive IIM remains a clinical challenge. Progress in the development and application of molecular biology techniques and biological therapeutics are evolving into a new scientific frontier in the management of autoimmune diseases. This review offers an update on those components of the humoral and cellular immunity deemed potential targets for biological therapeutics (monoclonal antibodies and fusion proteins) that have been approved by the US FDA for treatment of immunological disorders. A futuristic approach is envisioned in which each individual will receive targeted therapy tailored to patient-specific immune mechanisms. Risk-benefit and cost analyses should determine whether such targeted therapy is appropriate and feasible for refractive and/or newly diagnosed disease.

References

Couderc M, Gottenberg J, Mariette X, Hachulla E, Sibilia J, Fain O . Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology (Oxford). 2011; 50(12):2283-9. DOI: 10.1093/rheumatology/ker305. View

Walter M, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M . High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol. 2000; 247(1):22-8. DOI: 10.1007/s004150050005. View

Hengstman G, De Bleecker J, Feist E, Vissing J, Denton C, Manoussakis M . Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol. 2008; 59(3-4):159-63. DOI: 10.1159/000114036. View

Thomas T, Rollins S, Rother R, Giannoni M, Hartman S, Elliott E . Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996; 33(17-18):1389-401. DOI: 10.1016/s0161-5890(96)00078-8. View

Lundberg I, Ulfgren A, Nyberg P, Andersson U, Klareskog L . Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997; 40(5):865-74. DOI: 10.1002/art.1780400514. View

Stubgen J . Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies. J Neurol. 2011; 258(6):961-70. DOI: 10.1007/s00415-011-5907-2. View

Sallum A, Kiss M, Silva C, Wakamatsu A, Vianna M, Sachetti S . Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. Autoimmun Rev. 2006; 5(2):93-100. DOI: 10.1016/j.autrev.2005.05.008. View

Flores E, Bistrian B, Pomposelli J, Dinarello C, Blackburn G, Istfan N . Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. J Clin Invest. 1989; 83(5):1614-22. PMC: 303868. DOI: 10.1172/JCI114059. View

Hengstman G, van den Hoogen F, van Engelen B . Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opin Pharmacother. 2009; 10(7):1183-90. DOI: 10.1517/14656560902913815. View

10.

Levine T . Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005; 52(2):601-7. DOI: 10.1002/art.20849. View

11.

Pedrol E, Grau J, Casademont J, Cid M, Masanes F, Fernandez-Sola J . Idiopathic inflammatory myopathies. Immunohistochemical analysis of the major histocompatibility complex antigen expression, inflammatory infiltrate phenotype and activation cell markers. Clin Neuropathol. 1995; 14(3):179-84. View

12.

Iannone F, Scioscia C, Falappone P, Covelli M, Lapadula G . Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol. 2006; 33(9):1802-4. View

13.

Jain A, Sharma M, Sarkar C, Bhatia R, Singh S, Handa R . Increased expression of cell adhesion molecules in inflammatory myopathies: diagnostic utility and pathogenetic insights. Folia Neuropathol. 2009; 47(1):33-42. View

14.

Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R . Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 2005; 52(6):1824-35. DOI: 10.1002/art.21103. View

15.

Schmidt J, Dalakas M . Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. Expert Opin Med Diagn. 2013; 4(3):241-50. DOI: 10.1517/17530051003713499. View

16.

Kuru S, Inukai A, Kato T, Liang Y, Kimura S, Sobue G . Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies. Acta Neuropathol. 2003; 105(3):217-24. DOI: 10.1007/s00401-002-0635-4. View

17.

Cid M, Grau J, Casademont J, Tobias E, Picazo A, Coll-Vinent B . Leucocyte/endothelial cell adhesion receptors in muscle biopsies from patients with idiopathic inflammatory myopathies (IIM). Clin Exp Immunol. 1996; 104(3):467-73. View

18.

Bradshaw E, Orihuela A, McArdel S, Salajegheh M, Amato A, Hafler D . A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol. 2006; 178(1):547-56. DOI: 10.4049/jimmunol.178.1.547. View

19.

Englund P, Nennesmo I, Klareskog L, Lundberg I . Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in.... Arthritis Rheum. 2002; 46(4):1044-55. DOI: 10.1002/art.10140. View

20.

Mok C, Ho L, To C . Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol. 2007; 34(9):1864-8. View